ZyVersa Therapeutics, Inc. reported impairment charges for the second quarter ended June 30, 2023. For the period, the company reported impairment of goodwill of $11,895,033.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.86 USD | -1.62% | +12.76% | -46.00% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-46.00% | 3.69M | |
+15.55% | 121B | |
+12.66% | 107B | |
-2.53% | 24.82B | |
+1.75% | 22.48B | |
-9.35% | 18.32B | |
-42.28% | 16.33B | |
-18.92% | 15.31B | |
+6.19% | 14.08B | |
+28.83% | 11.74B |
- Stock Market
- Equities
- ZVSA Stock
- News ZyVersa Therapeutics, Inc.
- ZyVersa Therapeutics, Inc. Reports Impairment Charges for the Second Quarter Ended June 30, 2023